The invention relates to bispecific anti-sclerostin/anti-DKK1 binding agents and combinations of anti-sclerostin and anti-DKK1 binding agents, and related methods of treatment.
대표청구항▼
1. A binding molecule that specifically binds sclerostin and DKK-1 and comprises first and second polypeptide chains, wherein said first polypeptide chain comprises VH1-(X1)n-VH2-C-(X2)n, wherein VH1 comprises the amino acid sequence of SEQ ID NO: 95; wherein VH2 comprises the amino acid sequence of
1. A binding molecule that specifically binds sclerostin and DKK-1 and comprises first and second polypeptide chains, wherein said first polypeptide chain comprises VH1-(X1)n-VH2-C-(X2)n, wherein VH1 comprises the amino acid sequence of SEQ ID NO: 95; wherein VH2 comprises the amino acid sequence of SEQ ID NO: 4086; C is a heavy chain constant domain; (X1)n is a linker set forth in SEQ ID NO: 440 or SEQ ID NO: 441, and (X2)n is an Fc region and wherein said second polypeptide chain comprises a VL1-(X1)n-VL2-C, wherein VL1 comprises the amino acid sequence of SEQ ID NO: 94; wherein VL2 comprises the amino acid sequence of SEQ ID NO: 407; and wherein C is a light chain constant domain. 2. The binding molecule of claim 1, wherein the binding molecule comprises two first polypeptide chains and two second polypeptide chains. 3. The binding molecule of claim 1, wherein the Fc region is selected from the group consisting of a native sequence Fc region and a variant sequence Fc region. 4. The binding molecule of claim 1, wherein the Fc region is selected from the group consisting of an Fc region from an IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, and IgD. 5. The binding molecule of claim 1, wherein said binding molecule possesses at least one antibody parameter exhibited by said first parent antibody, or antigen binding portion thereof, or said second parent antibody, or antigen binding portion thereof, wherein said antibody parameter is selected from the group consisting of antigen specificity, affinity to antigen, potency, biological function, epitope recognition, stability, solubility, production efficiency, immunogenicity, pharmacokinetics, bioavailability, tissue cross reactivity, and orthologous antigen binding. 6. A binding molecule that binds both sclerostin and DKK-1 comprising four polypeptide chains, wherein first and third polypeptide chains comprise the amino acid sequence set forth in SEQ ID NO: 62 and wherein second and fourth polypeptide chains comprise the amino acid sequence set forth in SEQ ID NO: 64. 7. A binding molecule that binds both sclerostin and DKK-1 comprising four polypeptide chains, wherein first and third polypeptide chains comprise the amino acid sequence set forth in SEQ ID NO: 490 and wherein second and fourth polypeptide chains comprise the amino acid sequence set forth in SEQ ID NO: 492. 8. The binding molecule of claim 1, wherein said (X1)n of the VL1-(X1)n-VL2-C is SEQ ID NO: 440. 9. The binding molecule of claim 1, wherein said (X1)n of the VL1-(X1)n-VL2-C is SEQ ID NO: 441. 10. A method for generating a binding molecule that binds sclerostin and DKK-1 comprising the steps of: expressing said first, second, third and fourth polypeptide chains of claim 6 such that a binding molecule that binds sclerostin and DKK-1 is generated. 11. A pharmaceutical composition comprising the binding molecule of claim 6. 12. The binding molecule of claim 6 in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier. 13. A method of treating a bone disorder comprising administering to a patient in need thereof the binding molecule of claim 1. 14. A method of accelerating bone fracture repair comprising administering to a patient in need thereof the binding molecule of claim 1. 15. A method of increasing bone density comprising administering to a patient in need thereof the binding molecule of claim 1. 16. A method of increasing bone strength comprising administering to a patient in need thereof the binding molecule of claim 1.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (59)
Btzow Ralf (Helsinki CA FIX) Ruoslahti Erkki (Rancho Santa Fe CA), 60 kDa transforming growth factor-b
상세보기
Brunkow, Mary E.; Galas, David J.; Kovacevich, Brian; Mulligan, John T.; Paeper, Bryan W.; Van Ness, Jeffrey; Winkler, David G., Antibodies associated with alterations in bone density.
Brunkow, Mary E; Galas, David J; Kovacevich, Brian; Mulligan, John T; Paeper, Bryan W; Van Ness, Jeffrey; Winkler, David G, Antibodies associated with alterations in bone density.
Dan Michael D.,CAX ; Maiti Pradip K.,CAX ; Kaplan Howard A.,CAX, Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers.
Brunkow, Mary E; Galas, David J; Kovacevich, Brian; Mulligan, John T; Paeper, Bryan; Van Ness, Jeffrey; Winkler, David G, Compositions and methods for increasing bone mineralization.
Mary E. Brunkow ; David J. Galas ; Brian Kovacevich ; John T. Mulligan ; Bryan W. Paeper ; Jeffrey Van Ness ; David G. Winkler, Compositions and methods for increasing bone mineralization.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
Van Den Brink, Edward Norbert; De Kruif, Cornelis Adriaan; Throsby, Mark, Human bind molecules capable of neutralizing influenza virus h5n1 and uses thereof.
Yagi Kunio (Aichi-ken JPX) Noda Hitoshi (Aichi-ken JPX) Ohishi Nobuko (Gifu JPX) Kurono Masayasu (Mie-ken JPX), Liposome for entrapping gene, liposomal preparation and process for the manufacture of the preparation.
Stemmer Willem P. C. ; Crameri Andreas, Methods for generating polynucleotides having desired characteristics by iterative selection and recombination.
Margolis David J. (Philadelphia PA), Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures.
Dasch James R. (Palo Alto CA) Pace ; III Doran R. (San Francisco CA) Waegell Wendy O. (Mountain View CA), Monoclonal antibodies which bind both transforming growth factors bb<.
Mary E. Brunkow ; David J. Galas ; Brian Kovacevich ; John T. Mulligan ; Bryan W. Paeper ; Jeffrey Van Ness ; David G. Winkler, Nucleic acids encoding a novel family of TGF-.beta. binding proteins from humans.
Mary E. Brunkow ; David J. Galas ; Brian Kovacevich ; John T. Mulligan ; Bryan W. Paeper ; Jeffrey Van Ness ; David G. Winkler, Polypeptides associated with alterations in bone density.
Tsuchiya Masayuki,GB3 ; Sato Koh,GB3 ; Bendig Mary Margaret,GB3 ; Jones Steven Tarran,GB3 ; Saldanha Jose William,GB3, Reshaped human to human interleukin-6 receptor.
Liversidge Gary G. (West Chester PA) Cundy Kenneth C. (Pottstown PA) Bishop John F. (Rochester NY) Czekai David A. (Honeoye Falls NY), Surface modified drug nanoparticles.
Goldenberg Milton D. (11837 Gainsborough Rd. Potomac MD 20854), Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers.
Case, Ryan B.; Alba, Benjamin M.; Bakker, Alice; Chen, Irwin; Duguay, Amy N.; Florio, Monica; Li, Peng; Michaels, Mark Leo; Tsai, Mei-Mei, Inhibitory polypeptides specific to WNT inhibitors.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.